Esperion Therapeutics Historical PE Ratio image   This ESPR PE ratio history page last updated 3/12/2024
Esperion Therapeutics Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q4 2023
2/27/2024
2.90-0.50-2.00NA
Q3 2023
11/7/2023
1.03-0.37-1.48NA
Q2 2023
8/1/2023
1.69-0.46-1.84NA
Q1 2023
5/9/2023
1.42-0.79-3.16NA
Q4 2022
2/21/2023
5.59-0.76-3.04NA
Q3 2022
11/1/2022
8.28-0.81-3.24NA
Q2 2022
8/2/2022
5.87-1.05-4.20NA
Q1 2022
5/3/2022
6.53-0.93-3.72NA
Q4 2021
2/22/2022
4.36-1.77-7.08NA
Q3 2021
11/2/2021
10.31-2.62-10.48NA
Q2 2021
8/3/2021
14.27-1.67-6.68NA
Q1 2021
5/4/2021
25.59-3.50-14.00NA
Q4 2020
2/23/2021
27.88-3.89-15.56NA
Q3 2020
11/2/2020
28.99-3.07-12.28NA
Q2 2020
8/10/2020
37.004.3217.282.1
Q1 2020
5/6/2020
40.60-2.84-11.36NA
Q4 2019
2/27/2020
52.30-2.26-9.04NA
Q3 2019
11/6/2019
37.30-2.52-10.08NA
Q2 2019
8/8/2019
39.02-2.01-8.04NA
Q1 2019
5/8/2019
50.463.0712.284.1
Q4 2018
2/28/2019
46.10-2.24-8.96NA
Q3 2018
11/1/2018
49.94-1.86-7.44NA
Q2 2018
8/2/2018
47.72-1.71-6.84NA
Q1 2018
5/2/2018
45.75-1.73-6.92NA
Q4 2017
2/20/2018
75.79-1.44-5.76NA
Q3 2017
11/7/2017
49.15-1.86-7.44NA
Q2 2017
8/8/2017
52.13-1.92-7.68NA
Q1 2017
5/4/2017
36.94-1.80-7.20NA
Q4 2016
2/22/2017
22.53-1.29-5.16NA
Q3 2016
11/3/2016
9.40-0.77-3.08NA
Q2 2016
8/4/2016
10.97-0.62-2.48NA
Q1 2016
5/4/2016
14.37-0.65-2.60NA
Q4 2015
2/25/2016
14.97-0.58-2.32NA
Q3 2015
11/5/2015
27.50-0.57-2.28NA
Q2 2015
8/6/2015
55.61-0.55-2.20NA
Q1 2015
5/7/2015
99.98-0.56-2.24NA
Q4 2014
3/5/2015
63.16-0.49-1.96NA
Q3 2014
11/10/2014
25.83-0.64-2.56NA
Q2 2014
8/12/2014
15.86-0.60-2.40NA
Q1 2014
5/12/2014
14.23-0.51-2.04NA
Q4 2013
3/5/2014
16.38-0.63-2.52NA
Q3 2013
11/6/2013
14.77-0.34-1.36NA
Q2 2013
8/12/2013
17.23-19.82-79.28NA
Q1 2013
6/12/2013
NA-0.54-2.16NA
Esperion Therapeutics PE History Chart
PeriodPriceGAAPTTMPE
Q4 2023
2/27/2024
2.90-0.50-2.12NA
Q3 2023
11/7/2023
1.03-0.37-2.38NA
Q2 2023
8/1/2023
1.69-0.46-2.82NA
Q1 2023
5/9/2023
1.42-0.79-3.41NA
Q4 2022
2/21/2023
5.59-0.76-3.55NA
Q3 2022
11/1/2022
8.28-0.81-4.56NA
Q2 2022
8/2/2022
5.87-1.05-6.37NA
Q1 2022
5/3/2022
6.53-0.93-6.99NA
Q4 2021
2/22/2022
4.36-1.77-9.56NA
Q3 2021
11/2/2021
10.31-2.62-11.68NA
Q2 2021
8/3/2021
14.27-1.67-12.13NA
Q1 2021
5/4/2021
25.59-3.50-6.14NA
Q4 2020
2/23/2021
27.88-3.89-5.48NA
Q3 2020
11/2/2020
28.99-3.07-3.85NA
Q2 2020
8/10/2020
37.004.32-3.30NA
Q1 2020
5/6/2020
40.60-2.84-9.63NA
Q4 2019
2/27/2020
52.30-2.26-3.72NA
Q3 2019
11/6/2019
37.30-2.52-3.70NA
Q2 2019
8/8/2019
39.02-2.01-3.04NA
Q1 2019
5/8/2019
50.463.07-2.74NA
Q4 2018
2/28/2019
46.10-2.24-7.54NA
Q3 2018
11/1/2018
49.94-1.86-6.74NA
Q2 2018
8/2/2018
47.72-1.71-6.74NA
Q1 2018
5/2/2018
45.75-1.73-6.95NA
Q4 2017
2/20/2018
75.79-1.44-7.02NA
Q3 2017
11/7/2017
49.15-1.86-6.87NA
Q2 2017
8/8/2017
52.13-1.92-5.78NA
Q1 2017
5/4/2017
36.94-1.80-4.48NA
Q4 2016
2/22/2017
22.53-1.29-3.33NA
Q3 2016
11/3/2016
9.40-0.77-2.62NA
Q2 2016
8/4/2016
10.97-0.62-2.42NA
Q1 2016
5/4/2016
14.37-0.65-2.35NA
Q4 2015
2/25/2016
14.97-0.58-2.26NA
Q3 2015
11/5/2015
27.50-0.57-2.17NA
Q2 2015
8/6/2015
55.61-0.55-2.24NA
Q1 2015
5/7/2015
99.98-0.56-2.29NA
Q4 2014
3/5/2015
63.16-0.49-2.24NA
Q3 2014
11/10/2014
25.83-0.64-2.38NA
Q2 2014
8/12/2014
15.86-0.60-2.08NA
Q1 2014
5/12/2014
14.23-0.51-21.30NA
Q4 2013
3/5/2014
16.38-0.63-21.33NA
Q3 2013
11/6/2013
14.77-0.34NANA
Q2 2013
8/12/2013
17.23-19.82NANA
Q1 2013
6/12/2013
NA-0.54NANA
Quotes delayed 20 minutes

Email EnvelopeFree ESPR Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Esperion Therapeutics (ESPR) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

ETNB PE Ratio History
ETON PE Ratio History
ETTX PE Ratio History
EVFM PE Ratio History
EVLO PE Ratio History
EVOK PE Ratio History
EW PE Ratio History
EWTX PE Ratio History
EXAS PE Ratio History
EXEL PE Ratio History
How should the ESPR historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Esperion Therapeutics. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this ESPR Historical PE Ratio page.

What is the average historical PE for ESPR based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The ESPR historical PE ratio using the annualized quarterly earnings method works out to 3.1.

What is the average historical PE for ESPR based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The ESPR historical PE ratio using the TTM earnings method works out to NA.

On this page we presented the Esperion Therapeutics Historical PE Ratio information for Esperion Therapeutics' stock. The average ESPR historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 3.1. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average ESPR historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this ESPR historical PE result, against the recent PE: when this page was posted on 3/11/2024, the most recent closing price for ESPR had been 2.12, and the most recent quarterly earnings result, annualized, was 17.28. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent ESPR PE on 3/11/2024 based on annualized quarterly EPS was 0.1. Based on ESPR's history, that recent PE is low relative to the historical average, with the recent PE 96.8% lower than the historical average PE across our data set for Esperion Therapeutics.

For self directed investors doing their due diligence on ESPR or any other given stock, valuation analysis for ESPR can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Esperion Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for ESPR. Thanks for visiting, and the next time you need to research ESPR Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: AMWD Options Chain, LYV Historical Stock Prices, WMLP Options Chain.

 

Esperion Therapeutics Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2024, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.